Oct 30, 2017
Daiichi Sankyo Working with Berkeley Lights' Beacon(TM) OptoFluidic Platform for Cell Line Development
Oct 30, 2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
Oct 24, 2017
Milestone Pharmaceuticals Appoints Lorenz Muller as Chief Commercial Officer
Sep 14, 2017
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Sep 11, 2017
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
Sep 06, 2017
Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
Aug 31, 2017
Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
Aug 31, 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
Aug 31, 2017
Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting
Aug 31, 2017
Daiichi Sankyo Showcases New Insights on Multiple Oncology Compounds at the European Society for Medical Oncology (ESMO) 2017 Congress
Aug 29, 2017
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
Aug 28, 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Aug 01, 2017
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
Jun 30, 2017
Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
Jun 29, 2017
Heptares and PeptiDream Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Therapeutics in Inflammatory Disease
Jun 05, 2017
New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting